jm970364a_si_001.pdf (300.75 kB)
Synthesis and Pharmacological Characterization of 3-[2-((3aR,9bR)-cis-6-Methoxy- 2,3,3a,4,5,9b-hexahydro-1H- benz[e]isoindol-2-yl)ethyl]pyrido[3‘,4‘:4,5]thieno[3,2-d]pyrimidine- 2,4(1H,3H)-dione (A-131701): A Uroselective α1A Adrenoceptor Antagonist for the Symptomatic Treatment of Benign Prostatic Hyperplasia
journal contribution
posted on 1997-09-26, 00:00 authored by Michael D. Meyer, Robert J. Altenbach, Fatima Z. Basha, William A. Carroll, Irene Drizin, Steven W. Elmore, Paul P. Ehrlich, Suzanne A. Lebold, Karin Tietje, Kevin B. Sippy, Michael D. Wendt, Daniel J. Plata, Fred Plagge, Steven A. Buckner, Michael E. Brune, Arthur A. Hancock, James F. KerwinSynthesis and Pharmacological
Characterization of
3-[2-((3aR,9bR)-cis-6-Methoxy-
2,3,3a,4,5,9b-hexahydro-1H-
benz[e]isoindol-2-yl)ethyl]pyrido[3‘,4‘:4,5]thieno[3,2-d]pyrimidine-
2,4(1H,3H)-dione (A-131701): A
Uroselective α1A Adrenoceptor
Antagonist for the Symptomatic
Treatment of Benign Prostatic
Hyperplasia